S0931: EVEREST - EVErolimus for Renal Cancer Ensuring Surgical Therapy, A Phase III Study (H-29137):
This study will compare whether adding the oral drug everolimus vs. placebo for one year after surgery to remove kidney cancer will improve recurrence-free survival. The current standard treatment is monitoring after surgery. Patients must have had a full surgical resection with negative margins and all positive lymph nodes removed. Eligible patients must not have evidence of metastatic disease. All patients with be randomized to either everolimus or placebo for one year and then be followed for a total of 10 years from registration.
For additional information: http://clinicaltrials.gov/show/NCT01120249